<?xml version="1.0" encoding="UTF-8"?>
<p>The combination of pemetrexed with palbociclib enhanced the cytotoxicity of the antimetabolite in all cell lines tested (
 <xref ref-type="fig" rid="cancers-12-00713-f005">Figure 5</xref>A–C). Importantly, the calculation of the combination index indicated a synergistic effect in all cases, with the cytotoxic evaluation being comparable to the results obtained when antiviral efficacy was measured (
 <xref rid="cancers-12-00713-t003" ref-type="table">Table 3</xref>). The combination of fluorouracil with palbociclib enhanced fluorouracil potency in TZM-bl and T47D cells but not in MDA-MB-468 cell line (
 <xref ref-type="fig" rid="cancers-12-00713-f005">Figure 5</xref>A–C, 
 <xref rid="cancers-12-00713-t003" ref-type="table">Table 3</xref>). Interestingly, in MDA-MB-468 cells, although the expression of SAMHD1 was similar to other lines, Rb and pRb were not detected, either at the mRNA or protein level, (
 <xref ref-type="app" rid="app1-cancers-12-00713">Figure S3</xref>), demonstrating the importance of cell cycle proteins which putatively may affect SAMHD1 function in determining palbociclib–antimetabolite drug combination efficacy.
</p>
